The estimated Net Worth of Thomas E Shenk is at least $1.3 million dollars as of 20 July 2020. Thomas Shenk owns over 6,667 units of MeiraGTx plc stock worth over $655,100 and over the last 15 years he sold MGTX stock worth over $199,995. In addition, he makes $440,133 as Independent Director at MeiraGTx plc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Thomas Shenk MGTX stock SEC Form 4 insiders trading
Thomas has made over 3 trades of the MeiraGTx plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 6,667 units of MGTX stock worth $100,005 on 20 July 2020.
The largest trade he's ever made was selling 6,667 units of MeiraGTx plc stock on 20 July 2020 worth over $100,005. On average, Thomas trades about 635 units every 4 days since 2009. As of 20 July 2020 he still owns at least 157,476 units of MeiraGTx plc stock.
You can see the complete history of Thomas Shenk stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Thomas Shenk biography
Dr. Thomas E. Shenk Ph.D. serves as Independent Director of the Company. Dr. Shenk has served as a member of our Board of Directors since June 2015. Dr. Shenk has been the James A. Elkins Jr. Professor of Life Sciences in the Department of Molecular Biology at Princeton University since 1984. Dr. Shenk served on the board of directors of Merck and Co. Inc., a pharmaceutical company from 2001 to 2012. Dr. Shenk currently serves as a director of Vical Incorporated, a biopharmaceutical company, and served on the board of directors of Kadmon Holdings, Inc., a biopharmaceutical company, until June 2018. Dr. Shenk also currently serves as a member of each of the U.S. National Academy of Sciences, the U.S. National Academy of Medicine and the American Philosophical Society. He received a B.S. from University of Detroit and a Ph.D. from Rutgers University.
What is the salary of Thomas Shenk?
As the Independent Director of MeiraGTx plc, the total compensation of Thomas Shenk at MeiraGTx plc is $440,133. There are 12 executives at MeiraGTx plc getting paid more, with Alexandria Forbes having the highest compensation of $8,480,260.
How old is Thomas Shenk?
Thomas Shenk is 73, he's been the Independent Director of MeiraGTx plc since 2015. There are 1 older and 16 younger executives at MeiraGTx plc. The oldest executive at MeiraGTx Holdings plc is Arnold Levine, 80, who is the Independent Director.
What's Thomas Shenk's mailing address?
Thomas's mailing address filed with the SEC is 450 EAST 29TH STREET, 14TH FLOOR, NEW YORK, NY, 10016.
Insiders trading at MeiraGTx plc
Over the last 6 years, insiders at MeiraGTx plc have traded over $7,031,523 worth of MeiraGTx plc stock and bought 9,222,038 units worth $85,317,799 . The most active insiders traders include Advisors Llcperceptive Life..., Joel S Marcus et Life Sciences Master Fund L.... On average, MeiraGTx plc executives and independent directors trade stock every 33 days with the average trade being worth of $672,044. The most recent stock trade was executed by Advisors Llcperceptive Life... on 12 August 2024, trading 1,250,000 units of MGTX stock currently worth $5,000,000.
What does MeiraGTx plc do?
meiragtx, a london and new york-based gene therapy company, is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. we are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as alzheimer’s disease (ad), parkinson’s disease (pd), and amyotrophic lateral sclerosis (als). we are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (amd). meiragtx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
What does MeiraGTx plc's logo look like?
Complete history of Thomas Shenk stock trades at Kadmon Inc, Merck & Co Inc et MeiraGTx plc
MeiraGTx plc executives and stock owners
MeiraGTx plc executives and other stock owners filed with the SEC include:
-
Alexandria Forbes,
President, Chief Executive Officer, Director -
Richard Giroux,
Chief Financial Officer, Chief Operating Officer -
Dr. Alexandria Forbes,
CEO, Pres & Director -
Martin Indyk,
Independent Director -
Richard Brian Giroux B.A.,
COO & CFO -
Stuart Naylor,
Chief Development Officer -
Dr. Stuart Naylor Ph.D.,
Chief Devel. Officer -
Nicole Seligman,
Independent Director -
Keith Harris,
Independent Chairman of the Board -
Neil Mendoza,
Independent Director -
Joel Marcus,
Independent Director -
Arnold Levine,
Independent Director -
Thomas Shenk,
Independent Director -
Ellen Hukkelhoven,
Independent Director -
Elizabeth Broder,
Investor Relations -
Dr. Robert K. Zeldin M.D.,
Chief Medical Officer -
Dr. Alastair Leighton,
Sr. VP of Manufacturing & Supply Chain -
Tim Randall,
Sr. VP of Risk & Internal Controls -
Joel P. Brooks,
Sr. VP of Fin. -
Christine Elise Sheehy,
Sr. VP of Global Integration -
Dr. Michel Michaelides M.D.,
Head of Clinical Ophthalmology -
Robert J. Wollin J.D.,
Gen. Counsel & Sec. -
& Johnson Innovation Jjdc...,
10% owner -
Advisors Llcperceptive Life...,
-
Katherine Breedis,
Chief Financial Officer -
Life Sciences Master Fund L...,
-
Bruce Gottlieb,
General Counsel -
Advisors Llcedelman Joseph ...,
-
Debra Yu,
-
Robert K Zeldin,
CHIEF MEDICAL OFFICER -
Robert J Wollin,
GENERAL COUNSEL AND SECRETARY